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Abstract
A prominent histopathological feature of Sjo¨gren’s syndrome, an autoimmune disease, is the presence of lymphocytic
infiltrates in the salivary and lachrymal glands. Such infiltrates are comprised of activated lymphocytes and macrophages,
and known to produce multiple cytokines including interferon-gamma (IFN-c). In this study, we have demonstrated that
IFN-c strongly induces the expression of immunoproteasome beta subunits (b1i, b2i and b5i) and immunoproteasome
activity but conversely inhibits the expression of proteasome beta subunits (b1, b2 and b5) in human salivary gland (HSG)
cells. Mass spectrometric analysis has revealed potential MHC I-associated peptides on the HSG cells, including a tryptic
peptide derived from salivary amylase, due to IFN-c stimulation. These results suggest that IFN-c induces
immunoproteasomes in HSG cells, leading to enhanced presentation of MHC I-associated peptides on cell surface. These
peptide-presenting salivary gland cells may be recognized and targeted by auto-reactive T lymphocytes. We have also
found that lactacystin, a proteasome inhibitor, inhibits the expression of b1 subunit in HSG cells and blocks the IFN-c-
induced expression of b1i and immunoproteasome activity. However, the expression of b2i and b5i in HSG cells is not
affected by lactacystin. These results may add new insight into the mechanism regarding how lactacystin blocks the action
of proteasomes or immunoproteasomes.
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Introduction
Proteasomes are large protein complexes that function to
degrade a wide spectrum of proteins involved in the regulation of
cellular processes. The constitutive proteasome is a cylindrical
structure consisting of four stacked rings and two caps [1,2]. The
two inner rings are composed of seven beta (b) subunits containing
active protease-like sites. These proteolytic sites are located on the
interior surface of the rings, so that the target protein must enter
the central core for degradation. The two outer rings each consist
of 7 alpha subunits, which assemble a gating channel for proteins
to enter the proteasome ‘‘core’’. Formation of the 26S proteasome
also requires the addition of a regulatory cap structure to each end
of the four stacked rings. These caps recognize ubiquitinylated
proteins, unfold these degradation substrates and thread them into
the inner chamber of the proteasome complex where proteolysis
takes place.
In regular proteasomes, the b1, b2, and b5 subunits mediate
caspase-like, trypsin-like, and chymotrypsin-like activities, respec-
tively. These b subunits may be replaced by their bi counterparts
(b1i, b2i and b5i) in some cells when they are treated with
interferon-gamma (IFN-c), leading to the formation of immuno-
proteasomes. Compared to regular proteasomes, immunoprotea-
somes exhibit higher trypsin-like and chymotrypsin-like activities
and a lower caspase-like activity [3–5]. Peptides produced by
immunoproteasomes mainly contain hydrophobic or basic car-
boxyl termini which appear to be more efficient at binding to
MHC class I. Consequently immunoproteasomes are believed to
enhance the generation of antigenic peptides for MHC Class I
presentation [6–8].
Sjo¨gren’s syndrome (SS) is a chronic, autoimmune disease
causing dry mouth and eyes in ,4 million Americans [9,10]. A
prominent histopathological feature of SS is the presence of
lymphocytic infiltrates in the salivary and lachrymal glands. Such
infiltrates are comprised of activated lymphocytes and macro-
phages, and known to produce multiple cytokines including IFN-c.
IFN-c plays an important role in the pathogenesis of SS as
evidenced by previous studies. First, the salivary glands of SS
patients are infiltrated with massive amount of T lymphocytes.
These infiltrated T cells produce significant high levels of IFN-c
[11,12]. Second, constant stimulation of salivary gland cells with
IFN-c (1000 U/ml) has been shown to induce apoptosis of HSG
cells via up-regulation of Fas [13–15]. Third, animal model studies
suggested that IFN-c plays a critical role not only during the later
immune phase of SS, but also in the early pre-immune phase,
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independent of effector functions of immune cells. Compared to
non-obese diabetic (NOD) mice who develop SS-like symptoms,
both IFN-c and IFN-c receptor (IFN-cR) gene knockout NOD
mice (NOD.IFN-c-/- & NOD.IFN-cR-/-) showed no subsequent
autoimmune response against the salivary glands [16]. Last, Ro60
peptide immunization in the abdominal area of female Balb/c
mice led to increased levels of IFN-c and IL-12 systemically and
locally in the salivary glands. This implies that the mechanism of
action of Ro60 peptide immunization appears to involve an
increase in Th1 cytokines, resulting in the induction of salivary
gland dysfunction [17].
There have been few studies on the possible role of
immunoproteasome in SS pathogenesis [18–20]. In both infiltrat-
ing and peripheral immune cells, b1i expression was found to be
down-regulated in SS patients compared to healthy controls
[18,19]. On the other hand, b5i (LMP7) was found to be over-
expressed in the salivary gland epithelial cells of SS patients and
therefore suggested as a specific biomarker for SS diagnosis [20].
However, these studies did not reveal the MHC-associated
peptides presented on human salivary gland cells due to IFN-c-
mediated activation of immunoproteasomes in SS.
In this study, we have demonstrated that IFN-c induces the
expression of immunoproteasome b subunits but inhibits the
expression of constitutive b subunits in HSG cells. Immunoprotea-
some activity was found to be elevated in the IFN-c-treated HSG
cells, leading to the presentation of MHC I-associated peptides on
the cells. We have also shown that lactacystin, a proteasome
inhibitor, inhibits the expression of b1i and b1 subunits and
therefore blocks the IFN-c-mediated immunoproteasome activity
in HSG cells.
Results
IFN-c induces the expression of b1i, b2i and b5i in HSG
cells
To investigate the effect of IFN-c on the expression of
immunoproteasome beta subunits b1i, b2i and b5i, we treated
HSG cells with IFN-c (250 Units/ml) for 24, 48, 72 and 96 hours
and then compared the expression of b1i, b2i & b5i between
untreated and IFN-c-treated HSG cells with Western blotting. As
shown in Figure 1A, IFN-c induced the expression of all three b
subunits in HSG cells. Compared to untreated HSG cells, b1i
expression increased 2.7-, 6-, 6.9- or 7-fold (p,0.009) while b5i
expression increased 2.1-, 2.2-, 2.4- or 2.6-fold (p,0.002),
respectively, in HSG cells when treated with IFN-c for 24, 48,
72, and 96 hours. Significant induction of b2i expression was also
observed when HSG cells were treated with IFN-c for 24 hours
(4.4-fold) and 48 hours (4.1-fold). However, further treatment with
IFN-c for 72 and 96 hours resulted in significant decrease of b2i
expression in HSG cells.
IFN-c inhibits the expression of b1 and b5 in HSG cells
We also investigated the effect of IFN-c treatment on the
expression of constitutive b subunits, b1, b2 and b5 (Figure 1B).
Compared to untreated HSG cells, b1 expression decreased 2.0-,
3.0-, 2.9-, or 2.5-fold (p,0.002) while b5 expression decreased 1.6-
, 1.7-, 2.0-, or 2.2-fold (p,0.01), respectively, when HSG cells
were treated with IFN-c for 24, 48, 72 and 96 hours. The
expression of b2 in HSG cells was not significantly altered by IFN-
c treatment.
IFN-c up-regulates MHC I in HSG cells
Figure 1D shows the Western blot analysis of MHC class I in
untreated and IFN-c-treated HSG cells. IFN-c treatment signif-
icantly up-regulated the expression of MHC class I but not the
expression of MHC class II (data not shown) in HSG cells.
Identification of MHC I-associated peptides
In order to identify MHC I-associated peptides on untreated
and IFN-c-treated HSG cells, we used Co-IP to pull down the
MHC class I complex from HSG cells and then separated the
peptides from proteins within the MHC class I complex. The
isolated proteins were further digested with trypsin and the
resulting peptides were identified using LC-MS/MS and database
searching. MHC class I was identified from IFN-c-treated HSG
cells, with five peptides matched, and from untreated HSG cells
with 4 peptides matched. However, B2M was only identified from
IFN-c-treated HSG cells, with two unique peptides matched
(Table 1).
The isolated MHC I-associated peptides were directly analyzed
by LC-MS/MS (Table 2). Five MHC I-associated peptides were
identified from the IFN-c-treated HSG cells whereas none
identified from untreated HSG cells. The tandem MS spectrum
of LSGLLDLALGK, which is an MHC class I peptide originated
from salivary amylase is shown in Figure 2. These results imply
that IFN-c induces the expression of immunoproteasomes, leading
to the presentation of potential MHC I-associated peptides on
HSG cells.
Lactacystin inhibits IFN-c-induced expression of b1i
subunit in HSG cells
To investigate if a proteasome inhibitor, lactacystin, suppresses
IFN-c-induced expression of immunoproteasome b subunits, we
pre-treated HSG cells with lactacystin followed by IFN-c
treatment and then analyzed the expression of bi subunits in the
cells. As shown in Figure 3A, lactacystin did not significantly
affect the endogenous expression of b1i, b2i and b5i in HSG cells.
However, lactacystin pretreatment significantly inhibited the
expression of both precursor and mature forms of b1i in IFN-c-
treated HSG cells (p,0.004). The expression levels of b2i
(p = 0.19) and b5i (p = 0.09) in IFN-c-treated cells were not
significantly altered by lactacystin pre-treatment.
Lactacystin inhibits the expression of b1 in HSG cells
We also investigated the effect of lactacystin pre-treatment on
the expression of constitutive proteasome b subunits in HSG cells
(Figure 3B). Lactacystin significantly inhibited the expression of
b1 (2.7-fold, p = 0.003), slightly up-regulated the expression of b5
(1.5-fold, p = 0.04) but did not affect the expression of b2 in HSG
cells (lactacystin-treated versus untreated HSG cells). However,
when we compared HSG cells treated with both lactacystin and
IFN-c to those cells treated with IFN-c only, lactacystin pre-
treatment did not significantly alter the expression of b1 (1.2-fold,
p = 0.09) and b2 (1.1-fold, p= 0.39) but slightly up-regulated the
expression of b5 (1.4-fold, p = 0.006) in the IFN-c-treated HSG
cells.
On the other hand, when we compared HSG cells treated with
both lactacystin and IFN-c to those cells treated with lactacystin
only, the expression levels of b1 (1.07-fold, p = 0.75), b2 (1.2-fold,
p = 0.26) and b5 (0.88-fold, p= 0.33) in lactacystin-treated HSG
cells were not significantly affected by subsequent IFN-c stimu-
lation.
Lactacystin inhibits IFN-c-induced immunoproteasome
activities in HSG cells
As shown in Figure 4, IFN-c exposure increased immunopro-
teasome activities by 42–64% in HSG cells when the cells were
Immunoproteasomes in Human Salivary Gland Cells
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treated with IFN-c (250 U/ml) for 24–96 hrs. However, when the
cells were pre-treated with lactacystin, the IFN-c-induced im-
munoproteasome activities were significantly suppressed.
Discussion
SS is an autoimmune disease in which dry eyes (keratocon-
junctivitis sicca) and dry mouth (xerostomia) result from lympho-
cytic infiltration of lacrimal and salivary glands. During the
formation and proliferation of the lymphocytic infiltrates in SS
patients, IFN-c is significantly over-produced in salivary glands
and body fluids. For instance, both saliva and serum IFN-c levels
are 10-fold higher in SS patients than healthy individuals [11,12].
In fact, salivary gland CD4+ T cells from patients with SS produce
over 40-fold more IFN-c mRNA than those from normal controls
or the peripheral blood CD4+ T cells from the same patient. IFN-
c plays a critical role not only during the later immune phase of
SS, but also in the early pre-immune phase, independent of
effector functions of immune cells. Compared to NOD mice, both
IFN-c and IFN-cR gene knockout NOD mice (NOD.IFN-c-/- &
NOD.IFN-cR-/-) showed no subsequent autoimmune response
against the salivary glands [16]. IFN-c at a relatively high
concentration of 1000 U/ml causes anti-Fas mediated apoptosis
by inducing Fas at the surface of salivary gland epithelial cells [13–
15].
Our studies, however, suggest that IFN-c may play a role in SS
pathogenesis by inducing immunoproteasome activity in salivary
gland cells. We have found that IFN-c, at a relatively low level of
Figure 1. IFN-c induces the expression of immunoproteasome b subunits in HSG cells. The cells were treated with IFN-c at 250 U/ml for
24, 48, 72 or 96 hours. Western blotting was used to determine the levels of b1i, b2i and b5i (A) and proteasome b subunits b1, b2 and b5 (B) in IFN-c-
treated cells (n = 3 at each time point) and untreated cells (control, n = 2). (C) Normalized levels of immunoproteasome b subunits in relation to
constitutive proteasome b subunits in IFN-c-treated and untreated HSG cells. For each time point, three biological replicates (three cell lysates
samples obtained from three separate wells of the 6-well plate) were used for Western blot analysis and the error bars represent the standard
deviations at each time point. Computation of p values was done at each time point versus the control (untreated cells). *, p,0.05; **, p,0.01. (D)
Western blot analysis of MHC class I in untreated and IFN-c-treated HSG cells (250 U/ml for 24–96 hrs). *, p,0.05; **, p,0.01. Similarly, three
biological replicates at each experimental condition were used for the analysis.
doi:10.1371/journal.pone.0102878.g001
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250 U/ml, induces the expression of b1i, b2i and b5i but strongly
inhibits the expression of b1 and b5 in HSG cells. Constitutive b1,
b2 and b5 subunits are endogenously expressed in HSG cells,
forming constitutive proteasomes. However, under the stimulation
of IFN-c, b1, b2 and b5 are replaced by their bi counterparts, b1i,
b2i and b5i, leading to the formation of immunoproteasomes and
Table 1. LC-MS/MS identification of tryptic peptides from MHC class I or beta-2-microglobulin.
Peptides identified by LC-MS/MS
Protein name IFN-c-treated cells Untreated cells
MHC class I antigen FIAVGYVDDT QFVR FIAVGYVDDT QFVR
FIAVGYVDDT QFVR FIAVGYVDDT QFVR
FIAVGYVDDT QFVR EAGSHTIQMMYGCDVGPDGR YGCDVGPDGR
APWIEQEGPE YWDR AYLEGTCVEW LR
AYLEGTCVEW LR AYLEGTCVEW LR
AYLEGTCVEW LR DGEDQTQDTE LVETRPAGDGTFQK
DGEDQTQDTE LVETRPAGDGTFQK




Note: Redundant peptides are listed in the table because the peptide was detected two or more times.
doi:10.1371/journal.pone.0102878.t001
Figure 2. Tandem MS spectrum of MHC I-associated peptide, LSGLLDLALGK, originated from salivary amylase.
doi:10.1371/journal.pone.0102878.g002
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significantly increased immunoproteasome activities in HSG cells
(Figure 4). Thus, immunoproteasome becomes one of dominant
protein degradation mechanisms in IFN-c-treated HSG cells. We
will confirm these findings in our future studies. MS-based
quantitative method can be used to further validate the altered
expression of constitutive b1, b2 and b5 as well as immunoprotea-
some subunits b1i, b2i and b5i after the HSG cells are treated with
IFN-c. Similar experiments can be performed to study if IFN-c
induces immunoproteasome activities in primarily cultured
salivary gland cells, and two-dimensional gel electrophoresis with
MS may be used to investigate global protein changes altered by
IFN-c stimulation.
All the b subunits except b2 are synthesized as precursor
proteins with an N-terminal propeptide sequence. The C-termini
of beta subunits are on the outer surface of the proteasome
whereas the N-terminal proteolytic active sites are in the inner
surface. Upon assembling, the propeptides on the N-termini are
removed by an autocatalytic mechanism and thereby the b
subunits become catalytically activated [21]. The propeptides
function to inhibit premature proteolytic activity and serve as
chaperones to direct the proper proteasome assembly. They also
protect the mature subunits catalytic threonine 1 alpha-amino
group from acetylation [22]. In HSG cells, b1i, b2i and b5i are
present mainly in mature forms (21, 24 and 23 kDa, respectively).
As for the constitutive b subunits, b1 (24 kDa) and b5 (22 kDa) are
mainly expressed as the mature forms and there is no propeptide
sequence for b2.
In cells, constitutive proteasomes assemble first as half-
proteasomes consisting of an alpha and beta ring, with the b2
subunit binding first to the alpha subunits followed by b1 and lastly
b5 [23]. Two half proteasomes come together, which triggers the
autolysis of the propeptide sequences and the degradation of
proteassemblin, a chaperone [21,24]. A complete 20S proteasome
with 28 subunits is then formed, and the proteasome activator PA
700 binds to both ends of the 20S proteasome to allow entry of
protein for degradation. Although b2 expression is not significantly
affected by IFN-c in HSG cells, the assembly of constitutive
proteasomes can be diminished due to the expression of b1 is
abolished under IFN-c stimulation. Immunoproteasomes, howev-
er, assemble in a different order from constitutive proteasomes. b1i
subunit is incorporated first to the alpha subunits and b2i subunit
is then recruited. The incorporation of b2i into the proteasome
actually depends on the expression of b1i. In the presence of b1i
and b2i, the b5i subunit is incorporated last for the maturation of
the immunoproteasome [6]. Due to dramatically increased
expression of b1i, b2i and b5i in IFN-c treated HSG cells, the
assembly of immunoproteasomes is significantly enhanced and
may reach the highest level when the HSG cells are treated with
IFN-c for 48 hours (Figures 1 & 4).
IFN-c binds to its receptor on cell surface and activates the
JAK-STAT pathway which induces the transcription of many
genes. IFN-cR is indeed present on the ductal and acinar epithelia
of normal human salivary gland tissue [13,25]. Upon IFN-c
stimulation, many proteins may be altered in HSG cells due to the
activation of JAK/STAT pathway. Meanwhile, because IFN-c
activates immunoproteasomes in HSG cells, ubiquitinylated
proteins may be degraded by immunoproteasomes resulting in
decreased levels in HSG cells. Our studies have demonstrated that
IFN-c not only induces the expression of the immunoproteasome
b subunits, but also up-regulates the expression of MHC I in HSG
cells. This may be due to that b1i, b5i and MHC I share similar
promoter region [6,7,26]. b2i is located on chromosome 16 at
p22.1 whereas b1i and b5i genes are mapped to p21.3 of human
chromosome 6, the same region that contains the gene for MHC I.
Based on LC-MS/MS analysis, we found MHC class I on both
untreated and IFN-c-treated HSG cells whereas B2M, an
important component of MHC I complex, was only present on
IFN-c-treated HSG cells (Table 2). This not only indicates that
we successfully isolated the MHC I complex from the HSG cells
through the Co-IP approach, but also suggest that B2M is up-
regulated by IFN-c in HSG cells. We previously discovered that
the salivary levels of both B2M mRNA and protein are
significantly higher in the patients with SS than healthy
individuals. Further validation of B2M protein in a new SS
patient cohort confirmed that it is a highly sensitive biomarker for
SS [27,28].
Immunoproteasomes efficiently produce antigenic peptides for
MHC I presentation. Our studies suggested that potential MHC I
peptides are presented on HSG cells due to IFN-c stimulation.
Although these peptides need to be further confirmed as MHC I-
associated, several of them seem to have high binding affinity to
MHC I according to the NetMHC-3.0 MHC-I binding prediction
tool [29]. Autoimmune disease occurs when a specific adaptive
immune response is mounted against self antigens. Autoreactive T-
cells may be activated by MHC presentation of self-antigens,
leading to chronic inflammatory damage to tissues. As a result of
IFN-c-mediated activation of immunoproteasomes in HSG cells,
the peptides generated may be transported into endoplasmic
reticulum where they bind to the MHC I complex and then
presented on the cell surface. Autoreactive T cells are able to bind
to the peptide-MHC I complex and trigger an immune response if
the T cells recognize the peptides as non-self, causing the
destruction of salivary gland cells in patients with SS.
We found lactacystin strongly suppressed the expression of b1i
but did not significantly alter the expression of b5i and b2i in IFN-
c-treated cells. This might be because lactacystin plays an
inhibitory role of the transcriptional regulation of b1i. Previous
studies have indeed shown that lactacystin selectively reduces the
expression of surface protein B via down-regulating thyroid
transcription factor-1 [30]. b1i subunit is important for immuno-
proteasome assembly because it is the first b subunit that binds to
the alpha subunits. In fact, the bound b1i subunit recruits b2i and
Table 2. Potential MHC I-associated peptides on IFN-c-treated cells identified by LC-MS/MS.
Protein name MHC I peptides identified
Alpha amylase, salivary LSGLLDLALGK
Glyceraldehyde-3-phosphate dehydrogenase QASEGPLK
Splicing factor, arginine/serine-rich 130 LLTEILLDVTDEEIYY
Uncharacterized membrane protein C6orf72 NIMVVGITGAAVVI
Type II cytokeratin-1 SLDLDSIIAEVK
doi:10.1371/journal.pone.0102878.t002
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b5i to assemble an immunoproteasome [6]. Our findings imply
that lactacystin inhibits the formation of immunoproteasomes in
HSG cells via suppressing the expression of b1i.
Our study also shows that the expression levels of all constitutive
proteasome b subunits are not significantly affected by IFN-c if
HSG cells are pre-treated with lactacystin. On the other hand,
IFN-c treatment remains to strongly induce the expression of b2i
and b5i even though HSG cells are pretreated with lactacystin.
More importantly, lactacystin pretreatment strongly blocks the
induced expression of b1i by IFN-c in HSG cells.
In HSG cells without IFN-c treatment, the expression of b1 was
dramatically inhibited but b2 and b5 subunits were not
significantly affected by lactacystin. To form a 20S constitutive
proteasome, b2 subunit binds to the alpha subunits first; this is
followed by the binding of b1 and b5 subunits [6]. Therefore,
Figure 3. Effect of lactacystin pre-treatment on the expression of b1i, b2i, b5i, b1, b2 and b5 in HSG cells. (A) Western blot analysis of b1i,
b2i and b5i in HSG cells (n = 3 per group). (B) Western blot analysis of b1, b2 and b5 in HSG cells (n = 3 per group). At each experimental condition,
three cell lysates samples obtained from three separate wells of the 6-well plate were analyzed.
doi:10.1371/journal.pone.0102878.g003
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lactacystin also has an inhibitory effect on the proteasome
formation in HSG cells due to dramatic down-regulation of b1.
Previous studies concluded that lactacystin functions by binding
to the N-termini of the b subunits therefore inhibiting the
formation of proteasomes [31,32]. However, our studies suggest
that lactacystin may inhibit the formation of proteasomes or
immunoproteasomes in HSG cells by suppressing the expression of
b1 or b1i subunits.
In summary, our studies have demonstrated that IFN-c induces
the expression of immunoproteasome b subunits and immuno-
proteasome activity but suppresses the expression of constitutive
proteasome b subunits in HSG cells. Tandem MS analysis has
allowed us to identify peptides possibly presented by MHC class I
complex on HSG cells. In addition, lactacystin was found to
suppress the expression of b1 subunit and significantly block IFN-
c-induced expression of b1i and immunoproteasome activity in the
HSG cells. These results may add new insight into the mechanism
regarding how proteasome inhibitors block the action of
immunoproteasomes.
Our findings suggest a possible molecular mechanism underly-
ing SS pathogenesis. As a result of IFN-c over-expression in
patients with early SS onset, immunoproteasomes are activated in
salivary gland cells, leading to MHC I associated peptides
presented on salivary gland cells. These peptide-presenting cells
may be recognized and targeted by autoreactive T cells, causing
the destruction of salivary gland cells in patients with SS. If this
mechanism is further proven in human and mouse disease models,
treatment of SS or slow-down of SS progression in the patients
might be possible by targeting the peptide epitope(s) on HSG cells
or using proteasome inhibitors to suppress immunoproteasomes.
On the other hand, apoptosis of autoreactive T cells may be
selectively induced, even in advanced autoimmune disease, by the
introduction of the MHC class I and self-peptide complexes [33].
Materials and Methods
Cell culture and treatment
HSG cell line was initially established by Professor M. Sato of
Tokushima University in Japan [34]. The cells were cultured in
DMEM/F12 media supplemented with 10% fetal bovine serum
(Gemini) and 1% penicillin-streptomycin (Gibco). All cells were
maintained in a 5% CO2 incubator at 37uC.
HSG cells were treated with IFN-c at a concentration of
250 U/ml for 24, 48, 72 or 96 hours. For lactacystin studies, HSG
cells were pre-treated with 10 uM lactacystin for 1 hour and then
treated with IFN-c for 48 hours to investigate if lactacystin blocks
the effect of IFN-c stimulation.
Western blotting
To prepare cell lysates for Western blot analysis, HSG cells were
harvested and lysed with the 2-DE rehydration buffer. Total
protein assay was performed using the 2-D Quant Kit from GE
Healthcare.
Cell lysates (30 mg total proteins of each sample) were separated
with a 12% NuPAGE gel (Invitrogen) at 120 V for approximately
90 min and then transferred to nitrocellulose membrane using the
iBlot system (Invitrogen). Membranes were blocked with 5% milk
in TBST buffer for 2 hours and then incubated in a primary
antibody (Abcam: mouse monoclonal antibody to b1i, ab78336;
mouse monoclonal antibody to b2i, ab77735; mouse monoclonal
antibody to b5i, ab58094; mouse monoclonal antibody to b1,
ab21809; mouse monoclonal antibody to b2, ab22650; rabbit
polyclonal antibody to b5, ab78140; Thermo Fisher: mouse
monoclonal antibody to MHC I, W6/32, MA1-19027) overnight
at 4uC. Following incubation with secondary antibody horseradish
peroxidase-conjugated mouse or rabbit antibody (Applied Biolog-
ical Materials, Canada), protein bands were detected using the
ECL Kit (GE Healthcare). Scanned images were quantified with
Figure 4. IFN-c exposure increases immunoproteasome activities in HSG cells. The cells were treated with IFN-c (250 U/ml) for 24–96 hrs,
lysed with triton X-100, and then subjected to proteasome activity assay using fluorogenic substrate, Suc-LLVY-AMC. At each experimental condition,
three cell lysates samples obtained from three separate T25 flasks (n = 3) were analyzed. **, p,0.01.
doi:10.1371/journal.pone.0102878.g004
Immunoproteasomes in Human Salivary Gland Cells
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ImageJ (NIH) and ANOVA analysis (Tukey’s Post Hoc test) was
used to determine statistical differences between different treat-
ment groups.
Isolation and analysis of MHC I complex
M-280 tosylactivated Dynabeads (Invitrogen) were first washed
in 0.1 M borate buffer for five minutes while shaking. For the
coating procedure, the beads were incubated with W6/32
antibody, which recognizes the MHC class I when bound to
b2 M and peptide, for 36 hours at room temperature. After
incubation, the coated beads were washed twice in PBS/0.1%
BSA (pH 7.4) for 5 minutes at 4uC. The beads were then
incubated in 0.2 M Tris/0.2% BSA (pH 8.5) for 24 hours at room
temperature. Finally, the beads were washed twice in PBS/0.1%
BSA (pH 7.4) for 5 minutes at 4uC.
Cells were collected using a Cell Stripper (Cellgro, Mediatech)
and washed extensively with PBS, followed by re-suspension in
80 mM Na2HPO4 (pH 8.0). Cells were treated with papain
(0.125 mg/ml, Sigma) at 37uC in CO2 incubator for 90 minutes.
Following digestion, the cells were centrifuged at 13,000 g for 30
minutes at 4uC. The supernatant was concentrated using Amicon
Ultra 30K membrane (Millipore) at 500 g for 2 hours at 4uC. The
retentate containing MHC class I was added to the Dynabeads
coated with W6/32 monoclonal antibody for 3-hour incubation,
followed by extensive washes with PBS. Trifluoroacetic acid at
pH 2.1 was added to the beads to elute the bound MHC I, beta-2-
microglobulin (B2M) and peptide complex. The recovered effluent
was purified with Amicon Ultra 3K filter at 13,0006g for 1 hour
at 4uC. The filtrate containing the MHC class I peptides was
subjected to liquid chromatography with tandem mass spectrom-
etry (LC-MS-MS) using a nano-LC system (Eksigent Technology)
and LTQ ion trap mass spectrometer (Thermo Finnigan). LC
separation of peptides was performed with C18 PicoFrit capillary
columns (New Objectives) at a flow rate of 400 nL/min. Database
search was performed against the SwissProt database using the
SEQUEST (Thermo Finnigan). The following parameters were
used for database searching: enzyme specification, semi-tryptic/
semi-chymotryptic; missed cleavage allowed, one; Xcorr.2.0 (2+),
Xcorr.2.5 (3+). Meanwhile, to identify proteins within MHC I
complex, the retentate containing the MHC I complex proteins
was first reduced with 10 mM DTT for 30 min, followed by
alkylation with 50 mM iodoacetamide for 60 min in the dark, and
then digested with 10-ng trypsin at 37uC overnight. The resulting
peptides were identified by LC-MS/MS with database searching,
as described above.
Proteasome Activity Assay
After preparation of HSG cell lysates in 1.0% triton X-100
buffer, proteasome activities were measured using the Proteasome
Activity Assay Kit (APT280, Millipore) and fluorogenic substrate
Suc-LLVY-AMC according to the manufacturer’s manual. The
fluorescence was read with a fluorometer (Synergy HT Microplate
Reader, BioTek Instruments), and the excitation and emission
wavelengths were 380 and 460 nm, respectively.
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